CD8A and non-small cell lung carcinoma: Of these markers, NSCLC patients with a lower baseline proportion of CD4+ CM cells (<31%) or a higher baseline proportion of DN (CD4-CD8-CD3+) T cells (≥3%) experienced longer median PFS to ICI treatment.